Mitsubishi UFJ Trust & Banking

First State Investments is the consolidated asset management division of Commonwealth Bank of Australia, the largest financial institution in Australia and currently manages approximately €130 billion of investments globally. First State is a leading manager of, and investor in, infrastructure assets. With over twenty years’ experience in infrastructure investment, it is one of the longest established managers of infrastructure assets on behalf of institutional investors and currently manages in excess of €4.8 billion of equity invested across assets in the utility, transport and social infrastructure sectors in Australasia and Europe.

Synspective Inc. provides data by utilizing and integrating data from synthetic aperture radar satellite constellations, big data, and machine learning. It serves urban design, infrastructure, energy, insurance, and finance markets. The company is based in Tokyo, Japan.

Point Nine offers middle and back office services to Financial Institutions. Their operations team, combined with their proprietary developed web-based operations platform, help their clients to complement their existing middle and back office operations or even become their complete one-stop middle and back office solution.

ORPHE TRACK is a smart shoes platform that helps urban runners achieve their specific goals, as it enables a detailed review of user's running routine without any extra measurement equipment . Their latest crowdfunding campaign has been very successful on gathering early adopters concerned about their physical exercise improvements: https://www.makuake.com/project/evoride-orphe/ The startup provides customized experiences to be used not only for wellness but also for healthcare - both disease prevention and early detection.

SanBio Company Limited is a regenerative medicine firm based in Tokyo, Japan, specializing in the development of cell-based therapies for central nervous system disorders. The company is advancing SB623, a therapeutic product currently in Phase II clinical trials aimed at treating chronic motor deficits due to traumatic brain injury and stroke. In addition to SB623, SanBio's research pipeline includes various therapies for conditions such as age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson’s disease, Alzheimer’s disease, muscular dystrophy, cancer, and inflammatory diseases. The company has established collaborations with several academic institutions for the development and investigation of its therapies. Founded in 2001, SanBio is focused on leveraging innovative regenerative medicine to address unmet medical needs across a range of neurological and other health conditions.

SanBio Company Limited is a regenerative medicine firm based in Tokyo, Japan, specializing in the development of cell-based therapies for central nervous system disorders. The company is advancing SB623, a therapeutic product currently in Phase II clinical trials aimed at treating chronic motor deficits due to traumatic brain injury and stroke. In addition to SB623, SanBio's research pipeline includes various therapies for conditions such as age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson’s disease, Alzheimer’s disease, muscular dystrophy, cancer, and inflammatory diseases. The company has established collaborations with several academic institutions for the development and investigation of its therapies. Founded in 2001, SanBio is focused on leveraging innovative regenerative medicine to address unmet medical needs across a range of neurological and other health conditions.

Rydex Fund Services, Inc. provides transfer agency, accounting, compliance, and information technology services for the Rydex funds. The company was formerly known as PADCO Service Company Inc. and changed its name to Rydex Fund Services, Inc. in December, 2000.

Money Forward is a financial technology company that offers a range of services for individuals and corporations. It provides online personal accounting solutions that enable users to manage daily expenses by integrating data from bank accounts and credit cards. The platform is accessible on both desktop and mobile devices, including iOS and Android. In addition to personal financial management tools, Money Forward has developed a suite of cloud-based services tailored for businesses, which includes accounting software, tax return preparation, invoice management, payroll processing, and payment reconciliation. The company also engages users through economic media and an automatic savings app, as well as offering a communication channel where customers can interact with financial planners to address their financial concerns.

Solasia Pharma K.K., founded in 2006 and based in Tokyo, Japan, specializes in the development of oncology therapies and cancer care products. The company offers episil oral liquid, which provides pain relief, and Sancuso, a transdermal delivery system that administers granisetron to manage chemotherapy-induced nausea and vomiting. Solasia Pharma is also advancing its research pipeline with SP-02, a mitochondrial-targeted agent currently in Phase II clinical trials for various hematologic and solid cancers, and SP-04, which has completed Phase IIb clinical trials for chemotherapy-induced peripheral neuropathy.